The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1679
ISSUE 1679
June 26, 2023
Issue 1679
- Fezolinetant (Veozah) for Menopausal Vasomotor Symptoms
- Brexpiprazole (Rexulti) for Agitation in Alzheimer's Dementia
- In Brief: Expanded Heart Failure Indication for Dapagliflozin (Farxiga)
- In Brief: Alternatives to Mifepristone for Medication Abortion
- In Brief: OTC Ivermectin for Head Lice
- In Brief: Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma (online only)
- In Brief: A New Prostate Cancer Indication for Olaparib (Lynparza) (online only)
- In Brief: A New Prostate Cancer Indication for Darolutamide (Nubeqa) (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Fezolinetant (Veozah) for Menopausal Vasomotor Symptoms
June 26, 2023 (Issue: 1679)
Fezolinetant (Veozah – Astellas), a first-in-class
neurokinin 3 (NK3) receptor antagonist, has been
approved by the FDA for treatment of moderate to
severe vasomotor symptoms (VMS) due to menopause.
It is the second nonhormonal treatment to be...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.